Supplementary Table. Characteristics of the whole population with PMR (n=123).

Baseline characteristics		
Age (years), mean ± SD	70.7 ± 8.8	
Sex, female	82	(67)
Symptoms duration (weeks), median [95%CI]	12	[5; 20]
Shoulder pain	121	(98)
Pelvis girdle pain	88	(72)
Neck pain	48	(39)
Peripheral involvement	58	(47)
Constitutional symptoms	38	(31)
Symptoms suggesting LVV	20	(16)
CRP (mg/l) at PET/CT analysis, median [IQR]	32	[10; 70]
Patients with CST use	37	(30)
Dosage of CSTs (mg/day), mean ± SD	16.5 ± 15	
FDG-PET/CT characteristics		
Sites with significant FDG uptake (0-16), mean ± SD	9.5 ± 4.5	
Total SUVmax score, median [95%CI]	3.6	[3.1; 4.2]
Highest SUVmax, median [95%CI]	4.9	[4.1; 5.8]
Sites with significant FDG uptake (score ≥2) at patient level		
Acromioclavicular joint	45	(47)
Sternoclavicular joint	80	(65)
Shoulders	100	(81)
Cervical interspinous process	46	(37)
Lumbar interspinous process	89	(72)
Hips	94	(76)
Great trochanter	90	(73)
Symphysis pubis	69	(56)
Ischial tuberosity	100	(81)
Hand	49/105	(47)
LVV	17	(14)
Grade LVV, median [IQR]	3.9	[3.4; 4.5]

Data are n (%) patients unless indicated.
PMR: polymyalgia rheumatica; IQR: interquartile range; SUV: standardised uptake value; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; LVV: large-vessel vasculitis; FDG PET/CT: fluorodeoxyglucose positron emission tomography/computed tomography; SUV: standardised uptake value; CST: corticosteroids.